Patients with high expression of CSE1L exhibited shorter survival in breast cancer (GSE4922, GSE11121), brain tumor (GSE4271), liposarcoma (GSE30929), lung cancer (GSE13213), and ovarian cancer (GSE9891). This evidence concerns the gene CSE1L and liposarcoma.